EV 2022	Task Last Undeted	EV 06/20/2022
	Task Last Updated:	FY 00/30/2023
Validation of Multisystem Countermeasures Pro	tocol for Spaceflight during Antarctica v	vinter-over at Paimer Station
Human Research		
	TechPort:	No
(1) <b>HHC</b> :Human Health Countermeasures		
None		
brian.crucian-1@nasa.gov	Fax:	FY
NASA CENTER	Phone:	281-483-7061
NASA Johnson Space Center		
Immunology, SK4		
2101 NASA Pkwy		
Houston	State:	TX
77058-3607	<b>Congressional District:</b>	36
GROUND	Solicitation / Funding Source:	Directed Research
03/03/2021	End Date:	03/02/2026
	No. of PhD Degrees:	
	No. of Master' Degrees:	
	No. of Bachelor's Degrees:	
	Monitoring Center:	NASA JSC
Stenger, Michael	Contact Phone:	281-483-1311
michael.b.stenger@nasa.gov		
Dr. Crucian: Added Douglass Diak, Cody Gutier (both have departed out lab) (Ed., 9/15/23).	rrez, Jay Luna. Removed Georg Makedon	nas and Stephanie Krieger
<ul> <li>Nelman-Gonzalez, Mayra B.A. (NASA Johnson Space Center )</li> <li>Mehta, Satish Ph.D. (KBR/NASA Johnson Space Center )</li> <li>Smith, Scott Ph.D. (NASA Johnson Space Center )</li> <li>Zwart, Sara Ph.D. (NASA Johnson Space Center )</li> <li>Chouker, Alexander Ph.D. (University of Munich, Germany )</li> <li>Ponomarev, Sergey M.D., Ph.D. (Institute of Biomedical Problems (IBMP), Moscow, Russia )</li> <li>Simpson, Richard Ph.D. (University of Arizona )</li> <li>Stowe, Raymond Ph.D. (Microgen Laboratories )</li> <li>Wallace, Sara Ph.D. (NASA Johnson Space Center )</li> <li>Mercaldo, Nathaniel Ph.D. (NASA Johnson Space Center )</li> <li>Douglas, Grace Ph.D. (NASA Johnson Space Center )</li> <li>Downs, Meghan Ph.D. (NASA Johnson Space Center )</li> <li>Loisel, Dagan Ph.D. (St. Michael's College )</li> <li>VanderKaay Tomasulo, Melissa Ph.D. (St. Michael's College )</li> <li>Aunon-Chancellor, Serena MD (NASA Johnson Space Center )</li> <li>Marshall, Gailen M.D., Ph.D. (University of Mississippi )</li> <li>Orange, Jordan M.D., Ph.D. (Columbia University )</li> </ul>		
	Human Research         (1) HHC:Human Health Countermeasures         None         None         None         None         None         None         None         None         None         brian.crucian-1@nasa.gov         NASA CENTER         NASA Johnson Space Center         Immunology, SK4         2101 NASA Pkwy         Houston         77058-3607         GROUND         03/03/2021         Stenger, Michael         michael.b.stenger@nasa.gov         Dr. Crucian: Added Douglass Diak, Cody Gutier<(both have departed out lab) (Ed., 9/15/23).	Cucian, Brian Ph.D. Validation of Multisystem Countermeasures Protocol for Spaceflight during Antarctica V Human Research TechPort: (1) HHC:Human Health Countermeasures None None None None None None None None

Performance Gual No.:         Performance Gual Text:         Item Section and the section of the sectin of the section of the section of the section		Gershon, Anne M.D. (Columbia University)
Performance Gual No.:         Performance Gual Text:         Item Section and the section of the sectin of the section of the section of the section		Gutierrez, Cody (NASA Johnson Space Center)
Performance Goal Text: <ul> <li>Low-Farth onbial spaceflight porturbs the human immune system persistently, characterized by rocharlos in T and Kielen and the functional of latent benegovirus. While these alternitors have not caused widespeed clinical issues, some crewmenhos experience immune-clated adverse contained perspecter exploration missions will be of unprecedented duration, if is easonable is hypothesiz flat the immune entrubution of latent benegovirus. While these alternitors have not caused widespeed clinical issues, some erewmenhos experience immune-cluted adverse contained perspecter exploration missions will be of unprecedented duration, if is easonable is hypothesiz flat the immune contained perspecter exploration missions of exploration. Contained the synthesize the immune contained perspective and expected later durations in the synthese test is the developed a candidate multisystem immune contained perspective and expected later duration in trainage and perspective and expected later duration is flat by the hypothesiz flat the trainage expension of the developed and contained expected perspective and a set of secon-reliving exercises implemental long a wintur faily hypothesiz flat the trained is the contained expected perspective and excertises that are contained as the contained and the contotained and the contained and the contained and the co</li></ul>	Grant/Contract No.:	Directed Research
<ul> <li>Low-Earth orbital spaceflight partarbs the human immune system persistently, characterized by reductors in T and NK cell function, altered cytakine purfiles, and the reactivation of latest the preserves. While these depresents of the preserves in the entry of the preserves the immune depresentation of the entry of th</li></ul>	Performance Goal No.:	
Fail         Description:           Control of the second contene tof the second contene to the second control of the	Performance Goal Text:	
<ul> <li>1) Time to Implementation: Winter-over missions on Antarctica are yearlong deployments, which means opportunities to implement science there occur once a year. Initiating this project, concurrent with the planned NASA Johnson Space Center (JSC) Research and Clinical Advisory Panel/Technical Interchange Meeting (RCAPTIM), will expedite our ability to meet the Production Readiness Review (PRR) schedule for upcoming ground and flight validation of immune countermeasures. External solicitations would introduce unnecessary cost and delay study implementation, potentially by two years.</li> <li>2) Technical homology: The same measurements that have been used to define immune dysregulation during long-duration spaceflight will be used in this study to assess the efficacy of the countermeasure protocol. Furthermore, this constant set of parameters will be a valuable dataset against which to compare additional, cutting-edge means of immune surveillance. Without the consistency across studies, the result will be independent datasets, from which it will be impossible to formulate conclusions about the biological mechanisms at play. Many of the immune assays and endpoints included here have been validated during previous flight studies. To solicit for assays externally would invite technical differences from the flight studies that have defined immune dysregulation among astronauts in space, and produce a negative effect on data correlation.</li> <li>3) Validated sample processing protocols: The research teams listed in this proposal have already optimized and validated the protocols to ensure proper biological sample collection, stability, and storage under the operational constraints of fieldwork in Antarctica.</li> <li>4) Established collaborations: The NASA JSC investigators have a documented work relationship with the American and international partner immunologists listed in the protocol, which will expedite the execution of the study and ensure rapid and open communication between the teams.</li></ul>	Task Description:	<ul> <li>caused widespread clinical issues, some crewmembers experience immune-related adverse events, including manifestations of herpes virus reactivation, other infectious diseases, and atopic dermatitis. Because future deep-space exploration missions will be of unprecedented duration, it is reasonable to hypothesize that the immune perturbations observed aboard the International Space Station (ISS) will intensify during longer missions in deep space, thereby placing crewmembers at elevated clinical risk. Thus, it is imperative to preserve the immunocompetence of astronauts by developing a countermeasure strategy operationally compatible (mass, power, crew time, etc.) with implementation during deep space missions of exploration.</li> <li>An international team of interdisciplinary scientists has developed a candidate multisystem immune countermeasure protocol ready to test for efficacy, consisting of diet modification, nutritional supplementation, prescribed aerobic and resistive exercise, and a set of stress-relieving exercises implemented using a virtual reality headset. The isolation, extreme environment, prolonged duration, and various mission-associated stressors suggest the best Earth analog for spaceflight-induced immune dysregulation is likely to be Antarctica winter-over. Amongst the various Antarctic stations, one with small (ISS-like) crew size and normoxic (costal) conditions would be superior to evaluate the NASA countermeasure. The United States maintains three primary stations on Antarctica: Amundsen-Scott South Pole Station, McMurdo Station, and Palmer Station, of which only Palmer possesses and induces the desired characteristics that are most similar to the ISS. In this study, we will implement the countermeasures will positively rectify any immune dysregulation induced by the Palmer Antarctica spaceflight nanalog. This study will therefore validate the countermeasures suite prior to a potential flight validation aboard the ISS, and utilization during upcoming deep space missions.</li> <li></li></ul>
Research Impact/Earth Benefits:	Rationale for HRP Directed Research:	<ol> <li>Time to Implementation: Winter-over missions on Antarctica are yearlong deployments, which means opportunities to implement science there occur once a year. Initiating this project, concurrent with the planned NASA Johnson Space Center (JSC) Research and Clinical Advisory Panel/Technical Interchange Meeting (RCAP/TIM), will expedite our ability to meet the Production Readiness Review (PRR) schedule for upcoming ground and flight validation of immune countermeasures. External solicitations would introduce unnecessary cost and delay study implementation, potentially by two years.</li> <li>Technical homology: The same measurements that have been used to define immune dysregulation during long-duration spaceflight will be used in this study to assess the efficacy of the countermeasure protocol. Furthermore, this constant set of parameters will be a valuable dataset against which to compare additional, cutting-edge means of immune surveillance. Without the consistency across studies, the result will be independent datasets, from which it will be impossible to formulate conclusions about the biological mechanisms at play. Many of the immune assays and endpoints included here have been validated during previous flight studies. To solicit for assays externally would invite technical differences from the flight studies that have defined immune dysregulation among astronauts in space, and produce a negative effect on data correlation.</li> <li>Validated sample processing protocols: The research teams listed in this proposal have already optimized and validated the protocols to ensure proper biological sample collection, stability, and storage under the operational constraints of fieldwork in Antarctica.</li> <li>Established collaborations: The NASA JSC investigators have a documented work relationship with the American and international partner immunologists listed in the protocol, which will expedite the execution of the study and ensure rapid and open communication between the teams.</li>     &lt;</ol>
	Research Impact/Earth Benefits:	

Task Progress:	With the completion of the Antarctica Winter-Over (WO) 2022, samples have been successfully returned from Antarctica to NASA/JSC for further processing and distribution to Co-Investigators. WO 2023 has also commenced with 11 subjects consenting and performing their baseline data collections (BDCs) held in Chile. Another 5 subjects, who were already stationed at Palmer Station, Antarctica, asked to participate in the investigation. These 5 subjects were consented, but no BDC was able to be collected on them due to them joining in-mission. Therefore, there will now be a total of 16 subjects participating in Antarctica's 2023 Winter-Over, with a potential for 4 more participants to join if available.
Bibliography Type:	Description: (Last Updated: 09/15/2023)
Articles in Peer-reviewed Journals	Feuerecker M, Strewe C, Aumayr M, Heitland T, Limper U, Crucian B, Baatout S, Choukér A. "One year in the extreme isolation of Antarctica-Is this enough to modulate an "allergic" sensitization?" Biomedicines. 2022 Feb 15;10(2):448. <u>https://doi.org/10.3390/biomedicines10020448</u> ; PubMed <u>PMID: 35203657</u> ; PubMed Central <u>PMCID: PMC8962425</u> , Feb-2022